Please login to the form below

Not currently logged in
Email:
Password:

BMS and Janssen to assess PD1 cancer combination

Will test Opdivo and Imbruvica in non-Hodgkin lymphoma
Janssen Imbruvica iibrutinib

Janssen's Imbruvica (ibrutinib) is approved in the US to treat chromic lymphocytic leukaemia and mantle cell lymphoma

The potential for anti-PD1 cancer immunotherapies continues to grow with the announcement of another trial to test a combination treatment.

On this occasion Bristol-Myers Squibb (BMS) has teamed up with partners Janssen and Pharmacyclics to evaluate a combination of the PD1 drug Opdivo (nivolumab) and the oral Bruton's tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) in patients with non-Hodgkin lymphoma (NHL).

BMS' Opdivo is one of the leading anti-PD1 drugs, which work by binding to the checkpoint receptor PD1 expressed on activated T-cells to encourage the body's immune system to target cancerous cells.

Opdivo was approved as a melanoma treatment in Japan in the summer and is currently under review in a similar indication in both the US and Europe.

As with other anti-PD1 drugs - such as Merck & Co's FDA-approved Keytruda (ipilimumab) – hopes are high for Opdivo as both a monotherapy and in combination with existing cancer treatments that target tumours in different ways.

BMS has already signed agreements with several other companies to test Opdivo combinations. This includes a research collaboration with Celgene to test the drug in combination with Celgene's cancer drug Abraxane (paclitaxel) across multiple cancers and another deal agreed last week with Novartis to evaluate Opdivo in combination with several investigational drugs in lung cancer.

The latest deal with Janssen and Pharmacyclics further boosts the prospects of Opdivo, as well as Imbruvica, which is emerging as one of Janssen's key cancer prospects with US approvals in chromic lymphocytic leukaemia and mantle cell lymphoma and a recommendation for approval in the EU.

Janssen will conduct the phase I/II study to assess the safety and anti-tumour activity of the combination.

BMS' main competitor in the PD1 race Merck & Co also has collaborations in progress, including research partnerships with Advaxis, Pfizer, Amgen and Incyte.

Article by
Thomas Meek

14th October 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics